|
|
|
|
|
|
| (especial para SIIC © Derechos reservados) |
| Amparo Estellés* Autor invitado por SIIC |
|
 Profundizar Referencias bibliográficas |
| 1. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789-99. 2. Zondervan KT, Treloar SA, Lin J, Weeks DE, Nyholt DR, Mangion J, MacKay IJ, Cardon LR, Martin NG, Kennedy SH and Montgomery GW. Significant evidence of one or more susceptibility loci for endometriosis with near-Mendelian inheritance on chromosome 7p13-15. Hum Reprod 2007;22:717-28. 3. Cosín R, Gilabert-Estellés J, Ramón LA, Gómez-Lechón MJ, Gilabert J, Chirivella M, Braza-Boïls A, España F and Estellés A. Influence of peritoneal fluid on the expression of angiogenic and proteolytic factors in cultures of endometrial cells from women with endometriosis. Hum Reprod 2010; 25:398-405. 4. Gilabert-Estellés J, Castelló R, Gilabert J, Ramón LA, España F, Romeu A and Estellés A. Plasminogen activators and plasminogen activator inhibitors in endometriosis. In "Tissue Remodeling Factors in the Physiology and Pathophysiology of the Female Reproductive Tract". Front Biosc 2005; 10, 1162-1176 5. Gilabert-Estellés J, Estellés A, Gilabert J, Castelló R, España F, Falcó C, Romeu A, Chirivella M, Zorio E, and Aznar J. Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis. Hum Reprod 2003; 18:1516-1522. 6. Kobayashi H. Invasive capacity of heterotopic endometrium. Gynecol Obstet Invest 2000;50 Suppl 1:26-32. 7. Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P and Menger MD. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 2006; 21: 262-268. 8. Pan Q, Luo X, Toloubeydokhti T and Chegini N. The expression profile of micro-RNA in endometrium and endometriosis and the influence of ovarian steroids on their expression. Mol Hum Reprod 2007; 13: 797-806. 9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297. 10. Ambros V. The functions of animal microRNAs. Nature 2004; 16; 431: 350-355. 11. Ohlsson Teague EM, Print CG and Hull ML. The role of microRNAs in endometriosis and associated reproductive conditions. Hum Reprod Update 2010; 16: 146-165. 12. Kuokkanen S, Chen B, Ojalvo L, Benard L, Santoro N and Pollard JW. Genomic profiling of microRNAs and messenger RNAs reveals hormonal regulation in microRNA expression in human endometrium. Biol Reprod 2010; 82: 791-801. 13. Burney RO, Hamilton AE, Aghajanova L, Vo KC, Nezhat CN, Lessey BA and Giudice LC. MicroRNA expression profiling of eutopic secretory endometrium in women with versus without endometriosis. Mol Hum Reprod 2009; 15: 625-631. 14. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB, Bartel DP. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science. 2005,310:1817-21 15. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K.The microRNA spectrum in 12 body fluids. Clin Chem. 2010, 56:1733-41 16. Sonkoly E and Pivarcsi A. microRNAs in inflammation. Int Rev Immunol 2009; 28: 535-561. 17. Wittmann J, Jäck HM. Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta 2010, 1806:200-7 18. Suarez Y and Sessa WC. MicroRNAs as novel regulators of angiogenesis. Circ Res 2009; 104: 442-454. 19. Urbich C, Kuehbacher A and Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008; 79: 581-588. 20. Wu F, Yang Z and Li G. Role of specific microRNAs for endothelial function and angiogenesis. Biochem Biophys Res Commun 2009; 4: 549-553. 21. Ohlsson Teague EM, Van der Hoek KH, Van der Hoek MB, Perry N, Wagaarachchi P, Robertson SA, Print CG and Hull LM. MicroRNA-regulated pathways associated with endometriosis. Mol Endocrinol 2009; 23: 265-275 22. Donnez J, Smoes P, Gillerot S, Casanas-Roux F and Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 1998; 13: 1686-1690. 23. Girling JE and Rogers PA. Recent advances in endometrial angiogenesis research. Angiogenesis 2005; 8: 89-99. 24. Gilabert-Estellés J, Ramón LA, España F, Gilabert J, Vila V, Réganon E, Castelló R, Chirivella M and Estellés A. Expression of angiogenic factors in endometriosis: its relation to fibrinolytic and metalloproteinase (MMP) systems. Hum Reprod 2007; 22: 2120-2127. 25. Cosín R, Gilabert-Estellés J, Ramón LA, España F, Gilabert J, Romeu A and Estellés A. Vascular endothelial growth factor polymorphisms (-460C/T, +405G/C, and 936C/T) and endometriosis: their influence on vascular endothelial growth factor expression. Fertil Steril 2009; 92:1214-1220. 26. Kawano Y, Nakamura S, Nasu K, Fukuda J, Narahara H and Miyakawa I. Expression and regulation of thrombospondin-1 by human endometrial stromal cells. Fertil Steril 2005; 83:1056-1059 27. Ramón L, Gilabert-Estellés J, Castelló R, Gilabert J, España F, Romeu A, Chirivella M, Aznar J and Estellés A. mRNA quantitative analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using real-time reverse transcription-PCR assay. Hum Reprod 2005; 20: 272-278. |
| Otros artículos de Amparo Estellés |
| 1. Ramón L, Gilabert-Estellés J, Castelló R, Gilabert J, España F, Romeu A, Chirivella M, Aznar J, Estellés A. mRNA quantitative analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using real-time reverse transcription-PCR assay. Hum Reprod 2005;20: 272-8. 2. Castelló R, España F, Vázquez C, Fuster C, Almenar SM, Aznar J, Estellés A. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in human breast cancer and its association with tissue PAI-1 levels and severity tumor grade. Thromb. Res. 2006; 117:487-92. 3. Zorio E, Falcó C, Arnau MA, España F, Osa A, Ramón LA, Castelló R, Almenar L, Palencia MA, Estellés A. Lipoprotein(a) in young individuals as a marker of the presence of ischemic heart and the severity of coronary lesions. Haematologica 2006; 91:562-5. 4. Castelló R, Landete JM, España F, Vázquez C, Fuster C, Almenar SM, Ramón LA, Radtke KP, Estellés A. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Thromb. Res. 2007,120:753-62 5. Gilabert-Estellés J, Ramón LA, España F, Gilabert J, Vila V, Réganon E, Castelló R, Chirivella M, Estellés A. Expression of angiogenic factors in endometriosis: its relation to fibrinolytic and metalloproteinase (MMP) systems. Hum Reprod 2007; 22:2120-7. 6. Ramón LA, Gilabert-Estellés J, Cosín R, Gilabert J, España F, Castelló R, Chirivella M, Romeu A, Estellés A. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression. Thromb Res, 2008; 122:854-60. 7. Ricart JM, Ramón LA, Vayá A, España F, Santaolaria ML, Todolí J, Castelló R, Fontcuberta J, Estellés A. Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis. Br J Haematol 2008; 141:716-9. 8. Zorio E, Gilabert-Estelles J, España F, Ramon LA, Cosin R, Estellés A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 2008, 15:923-9. 9. Cosín R, Gilabert-Estellés J, Ramón LA,. España F, Gilabert J, Chirivella M, Romeu A, Estellés A. Vascular endothelial growth factor (VEGF) polymorphisms (-460C/T, +405G/C and 936C/T) and endometriosis. Influence of these three functional polymorphisms in VEGF expression. Fert & Steril 2009;92:1214-20. 10. Cosín R, Gilabert-Estellés J, Ramón LA, Gómez-Lechón MJ, Gilabert J, Chirivella M, Braza-Boïls A, España F, Estellés A. Influence of peritoneal fluid on the expression of angiogenic and proteolytic factors in endometrial cell culture from endometriosis. Hum Reprod 2010, 25:398-405. |
|
Acerca del trabajo completo |
| EXPRESIÓN ALTERADA DE MICRORNA RELACIONADOS CON LA ANGIOGÉNESIS EN LA ENDOMETRIOSIS |
| Título original en castellano EXPRESIÓN DE MICRORNA EN LA ENDOMETRIOSIS: SU RELACIÓN CON FACTORES ANGIOGÉNICOS |
| Autores Amparo Estellés1, Luis A. Ramón2, Juan Gilabert-Estellés3, Aitana Braza-Boïls4, Juan Gilabert5, Francisco España6, Melitina Chirivella7 |
| 1 Doctor en Medicina y Cirugía, Hospital Universitario la Fe, Facultativo Especialista 2 Doctor en Biología, Hospital Universitario la Fe. Valencia, Investigador 3 Doctor en Medicina y Cirugía, Hospital Universitario Doctor Peset. Valencia, Facultativo Especialista 4 Doctora en Biología, Hospital Universitario la Fe. Valencia, Investigadora 5 Doctor en Medicina y Cirugía, Hospital Arnau de Vilanova. Valencia, Jefe de Servicio de Ginecología 6 Doctor en Ciencis Químicas, Hospital Universitario la Fe. Valencia, Jefe de Sección 7 Licenciada en Medicina y Cirug, Hospital Universitario la Fe. Valencia, Facultativo Especialista |
| Acceso a la fuente original Human Reproduction |
| http://humrep.oupjournals.org/ |
| El artículo se relaciona estrictamente con las especialidades de siicsalud | |
|
ua90911 |
Acerca de SIIC Estructura de SIIC
|
|
Sociedad Iberoamericana de Información Científica (SIIC)
Av. Belgrano 430, (C1092AAR), Buenos Aires, Argentina Tel: +54 11 4342 4901; Fax: +54 11 4331 3305 Casilla de Correo 2568, (C1000WAZ) Correo Central, Buenos Aires Copyright siicsalud© 1997-2013, Sociedad Iberoamericana de Información Científica (SIIC) ISSN siicsalud: 1667-9008 ua4711 Mensajes a SIIC |
